Kukje Pharma Co., Ltd. (KRX:002720)

Market Cap	88.58B -7.5%
Revenue (ttm)	175.50B +12.2%
Net Income	5.70B +9.5%
EPS	280.00 +9.4%
Shares Out	20.36M
PE Ratio	15.54
Forward PE	n/a
Dividend	30.00 (0.71%)
Ex-Dividend Date	Mar 12, 2026

Volume	95,352
Average Volume	182,748
Open	4,355.00
Previous Close	4,350.00
Day's Range	4,170.00 - 4,370.00
52-Week Range	4,050.00 - 5,470.00
Beta	0.40
RSI	30.11
Earnings Date	Apr 2, 2026

About Kukje Pharma

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAID...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 248
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 002720

Financial Performance

In 2025, Kukje Pharma's revenue was 175.50 billion, an increase of 12.16% compared to the previous year's 156.46 billion. Earnings were 5.70 billion, an increase of 9.46%.